Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

The Monday night Plan Commission vote means Mounjaro ... Eli Lilly and Co.'s contractors can seek permits for construction. Eli Lilly and Co. won village of Pleasant Prairie approval for its final ...

Eli Lilly is leaving nothing to chance when it comes to making the most of its fast-growing diabetes therapy Mounjaro – it ... for parenteral filling, device assembly, and packaging even further.

Around 180,000 people with type 2 diabetes in the UK could be in line for treatment with Eli Lilly's Mounjaro after the drug was recommended for NHS use by cost-effectiveness overseer NICE.

Eli Lilly’s profit ... expected 2025 forecast. Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity ...

Eli Lilly (LLY) launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk (NVO) for a much-awaited entry into the world’s most populous ...

Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro, in India, outpacing competitor Novo Nordisk. With ...

Lilly beats Novo Nordisk to launch weight-loss drug in India Mounjaro's 5 mg vial priced at around $50, 2.5 mg at about $40 Drug's pricing may limit accessibility in India, analyst says Novo's ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India, marking its entry into a rapidly growing market.